Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395378 | 0.92 | PRKCA (0.50) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL393139 | 0.89 | PRKCA (0.39) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL2277958 | 0.87 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL2278540 | 0.84 | PRKCA (0.43) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL391531 | 0.82 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL395104 | 0.80 | PRKCA (0.65) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL394394 | 0.79 | PRKCA (0.46) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL393270 | 0.78 | PRKCA (0.51) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL4213725 | 0.78 | NR1I2 (0.44) | PRKCAMMP12NR1I2KCNH2CYP3A4 | |
| SCHEMBL4213738 | 0.77 | NR1I2 (0.42) | PRKCAMMP12NR1I2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121707-B1 | ANTIVIRAL INDOLES | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-12-05 | — | — | EP | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | PRKCA 4625/4885MMP12 2333/4885NR1I2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.